Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rosneft optionality makes BP 'prime ceasefire beneficiary', says JPMorgan

(Sharecast News) - JPMorgan Cazenove upgraded BP on Thursday as it took a look at EU oil and gas stocks and considered the implications of a Russia/Ukraine ceasefire. The bank said it expects the sector to be viewed as a net loser as the market infers a peace deal bringing additional Russian pipeline gas flows into Europe.

It noted that to date, high-end TTF geared names like 'overweight' Equinor and Var appear to have efficiently discounted lower prices.

"However, we caution an imminent and meaningful resumption of flows appears far from straightforward, while select corporates also retain legacy Russian asset option value," JPM said.

"Our fundamental preference is for superior barbells of leverage and resilience, and core overweights Shell, TotalEnergies remain well placed."

The bank upgraded BP to 'neutral' from 'underweight' and lifted the price target to 510p from 440p as it said the outsized Rosneft option value mitigates cash cycle tensions.

"Rosneft optionality makes BP a prime ceasefire beneficiary," the bank said. "This presents a deleveraging 'silver bullet' which mitigates previously analysed cash cycle tensions."

Meanwhile, it double downgraded OMV to 'underweight' and cut the price target to €40 from €46 following a recent petrochemical hedge inspired rally which it said leaves the valuation and consensus earnings per share "appearing full".

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.